Justin T.Smith

Associate

Irvine + 1.949.553.7594

Justin Smith advises public and private companies on corporate and securities law focusing on cross-border and domestic mergers and acquisitions as well as corporate governance, debt and equity investments, and licensing and commercial agreements. His cross-border experience includes transactions involving Brazil, Canada, China, France, Germany, Japan, Mexico, the Netherlands, Switzerland, and the United Kingdom.

Justin represents clients from a broad range of industries, including biopharmaceutical, medical device, pharmaceutical, technology, energy, telecommunications, and retail. Representative clients include Abbott Laboratories, AbbVie, Advantage Solutions, Allergan, Ambry Genetics, Billabong International, BioMarin Pharmaceutical, Celgene Corporation, Experian Information Solutions, the Internet Corporation for Assigned Names and Numbers (ICANN), Kyowa Hakko Kirin, Linear Technologies, Neurotech Pharmaceuticals, Oclaro, SAP AG, SunPower Corporation, and TDK Corporation.

Recent representations include Linear Technology's $14.8 billion sale to Analog Devices; Oclaro's $1.8 billion sale to Lumentum Holdings; TDK Corporation's $1.3 billion acquisition of InvenSense; Ambry Genetics' $1.0 billion sale to Konica Minolta; Advantage Solution's acquisitions of The Data Council, Quiverr Collective, and Upshot, Inc.; and ICANN in connection with the successful completion of the transition of the Internet Assigned Numbers Authority functions from the U.S. National Telecommunications and Information Administration to ICANN.

Experience

  • Furukawa Electric and Superior Essex global joint venture finalizedJones Day advised Furukawa Electric Co., Ltd. in its finalization of a global joint venture with Superior Essex Inc.
  • Playboy to become public company by combining with Mountain Crest Acquisition Corp.Jones Day is advising Playboy Enterprises, Inc. in its definitive merger agreement with Mountain Crest Acquisition Corp. (Nasdaq: MCAC) ("Mountain Crest"), a publicly-traded special purpose acquisition corporation (SPAC), whereby Playboy shareholders will be entitled to receive shares of common stock in Mountain Crest, and Mountain Crest will assume outstanding Playboy debt, for a total purchase price valued at approximately $381 million.
  • Synaptics divests LCD TDDI business to Hua Capital for $139.4 millionJones Day advised Synaptics Incorporated in its $139.4 million divestiture of its Asia-based mobile LCD TDDI Business to an affiliate of Hua Capital.
  • Advantage Solutions acquires full-service brand, digital, and experiential agencyJones Day advised Advantage Solutions in its acquisition of a full-service brand, digital, and experiential agency.
  • Advantage Solutions acquires leading brand manager and marketing agencyJones Day advised Advantage Solutions in its acquisition of a leading brand manager and sales and marketing agency.
  • Ambry Genetics® acquires next-generation sequencing systemsJones Day advised Ambry Genetics® in its acquisition of next-generation sequencing systems.
  • Misonix acquires Solsys Medical, LLC for $109 millionJones Day advised Misonix, Inc. in its acquisition of Solsys Medical, LLC, a privately held regenerative medical company, in an all-stock transaction valued at approximately $109 million.
  • Evidera acquires MedimixJones Day advised Evidera, a business unit of Pharmaceutical Product Development, LLC, in its acquisition of Medimix International, a global technology company providing real-world evidence (RWE) insights and information to the pharmaceutical, diagnostic, and medical device industries.
  • Cylance acquired by BlackBerry for $1.4 billionJones Day advised Cylance, an artificial intelligence and cybersecurity leader, in its $1.4 billion acquisition by BlackBerry Limited, plus the assumption of unvested employee incentive awards.
  • Oclaro sold to Lumentum for $1.8 billion in cash and stockJones Day advised Oclaro, Inc. in its $1.8 billion acquisition by Lumentum Holdings Inc.
  • Advantage Solutions acquires Jun GroupJones Day advised Advantage Solutions on its acquisition of Jun Group, an industry-leading mobile video advertising company.
  • Advantage Solutions acquires Daymon WorldwideJones Day advised the management team of Advantage Solutions, a leading North American provider of business solutions to consumer goods manufacturers and retailers, with a suite of technology-enabled services that includes headquarter sales representation, business intelligence, merchandising, and marketing solutions, in its acquisition of Daymon Worldwide.
  • Ambry Genetics sold to joint venture formed by Konica Minolta and Innovation Network for up to $1.0 billionJones Day advised Ambry Genetics Corporation, a leading genetic testing corporation, in its sale to a newly formed joint venture between Konica Minolta, Inc. and Innovation Network Corporation of Japan for up to $1.0 billion (including earnouts).
  • Advantage Solutions acquires The Data CouncilJones Day advised Advantage Solutions in the acquisition of The Data Council, the leading provider of verified and standardized product data and images.
  • Advantage Solutions acquires QuiverrJones Day advised Advantage Solutions in its acquisition of Quiverr Collective, LLC.
  • TDK acquires InvenSense for $1.3 billionJones Day advised TDK Corporation in its $1.3 billion acquisition of InvenSense, Inc.
  • Linear Technology acquired by Analog Devices for $14.8 billionJones Day advised Linear Technology Corporation on its sale to Analog Devices, Inc.
  • ICANN advised in connection with governance reform and transition of IANA functionsJones Day advised Internet Corporation for Assigned Names and Numbers (ICANN) in connection with the successful completion of the transition of the Internet Assigned Numbers Authority (IANA) functions from the U.S. National Telecommunications and Information Administration to ICANN.
  • Advantage Solutions acquires consumer marketing agency UpshotJones Day advised Advantage Solutions in its acquisition of Upshot, Inc., an industry-leading, consumer marketing agency based in Chicago.
  • BioMarin acquires global rights to Phenylketonuria (PKU) franchise from Merck Serono for $588.8 millionJones Day advised BioMarin Pharmaceutical Inc. in connection with its €525 million ($588.8 million) acquisition of the global rights to Kuvan® (sapropterin dihydrochloride) and pegvaliase from Merck Serono.
  • We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.